NCT00785681

CompletedPhase 3

Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Compatibi...

Sanofi Source

Compare

Other study identifiers

Sponsor study identifier

LACAC_L_04302

Study Type

interventional

Actual enrollment (reported)

53

Locations

1 country

Sites

1

Timeline

Study Start

July 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

September 2008

Actual (reported)

Study Completion

September 2008

Actual (reported)

Brief Summary

The purpose of this study is to demonstrate the absence of irritation potential (primary dermical irritability and cumulated dermical irritability) and allergy (sensibilization) of the product Dermacyd PHDETINBACK Sweet Flower.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 53 participants
Study completion date: September 2008
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2008
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
September 2008
Actual (reported)
Study Completion
September 2008
Actual (reported)
First Submitted
November 4, 2008
Actual (reported)
First Posted
November 5, 2008
Actual (reported)

Last Updated: August 25, 2009
Status Verified: August 2009
Last Update Submitted: August 21, 2009

Conditions

Hygiene

Outcome Measures

Primary Outcomes (1)

The absence of primary and accumulated dermical irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.
Throughout the study

Study Arms (1)

1

EXPERIMENTAL

Dermacyd PH\_DETINBACK (Lactic Acid)

Drug: Dermacyd PH_DETINBACK (Lactic Acid)

Interventions

Dermacyd PH_DETINBACK (Lactic Acid)Drug

1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 60 Years

Sexfemale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Phototype Skin I,II, III e IV
Integral skin test in the region;

Sponsors & Collaborators

Sanofi
Industrylead

Study Sites (1)

Sanofi-Aventis Administrative Office

São Paulo, Brazil

MeSH Terms

Interventions

Lactic Acid

Intervention Hierarchy (Ancestors)

LactatesHydroxy AcidsCarboxylic AcidsOrganic Chemicals

Study Officials

Jaderson Lima
Sanofi
STUDY DIRECTOR

Enrollment

53 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: SUPPORTIVE CARE
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

November 4, 2008

First Posted

November 5, 2008

Study Start

July 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00784160

Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid)- Compatibility

Phase 3Completed

NCT00785590

Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.

Phase 3Completed

NCT00785148

Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety

Phase 3Completed

NCT00933907

Dermacyd PH_DESILSTY_FR (Lactic Acid) - Compatibility - Stay on Frutal

Phase 3Completed

NCT00786097

Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix - Compatibility

Phase 3Completed

NCT00784121

Dermacyd Breeze (Lactic Acid) Pocket BR - Compatibility

Phase 3Completed

Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

You may not qualify if:

Lactation or gestation
Use of Antiinflammatory and/or immunosuppression drugs
Personnel history of atopy;
History of sensitivity or irritation for topic products;
Active cutaneous disease;
Use of new drugs or cosmetics during the study
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contact the study team to confirm eligibility.

Primary Completion

September 2008

Actual (reported)

Study Completion

September 2008

Actual (reported)

Last Updated

August 25, 2009

Record last verified: 2009-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00785681
Data provider: ClinicalTrials.gov
Source updated: 2009-08-25
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:25 UTC

Locations

BR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations